135 related articles for article (PubMed ID: 17823293)
1. Disordered purinergic signaling inhibits pathological angiogenesis in cd39/Entpd1-null mice.
Jackson SW; Hoshi T; Wu Y; Sun X; Enjyoji K; Cszimadia E; Sundberg C; Robson SC
Am J Pathol; 2007 Oct; 171(4):1395-404. PubMed ID: 17823293
[TBL] [Abstract][Full Text] [Related]
2. Deletion of cd39/entpd1 results in hepatic insulin resistance.
Enjyoji K; Kotani K; Thukral C; Blumel B; Sun X; Wu Y; Imai M; Friedman D; Csizmadia E; Bleibel W; Kahn BB; Robson SC
Diabetes; 2008 Sep; 57(9):2311-20. PubMed ID: 18567823
[TBL] [Abstract][Full Text] [Related]
3. Overexpression of CD39/nucleoside triphosphate diphosphohydrolase-1 decreases smooth muscle cell proliferation and prevents neointima formation after angioplasty.
Koziak K; Bojakowska M; Robson SC; Bojakowski K; Soin J; Csizmadia E; Religa P; Gaciong Z; Kaczmarek E
J Thromb Haemost; 2008 Jul; 6(7):1191-7. PubMed ID: 18485080
[TBL] [Abstract][Full Text] [Related]
4. Ectonucleotidases as regulators of purinergic signaling in thrombosis, inflammation, and immunity.
Deaglio S; Robson SC
Adv Pharmacol; 2011; 61():301-32. PubMed ID: 21586363
[TBL] [Abstract][Full Text] [Related]
5. Class 3 semaphorins control vascular morphogenesis by inhibiting integrin function.
Serini G; Valdembri D; Zanivan S; Morterra G; Burkhardt C; Caccavari F; Zammataro L; Primo L; Tamagnone L; Logan M; Tessier-Lavigne M; Taniguchi M; Püschel AW; Bussolino F
Nature; 2003 Jul; 424(6947):391-7. PubMed ID: 12879061
[TBL] [Abstract][Full Text] [Related]
6. IL-4 prevents adenosine-mediated immunoregulation by inhibiting CD39 expression.
Fang F; Cao W; Mu Y; Okuyama H; Li L; Qiu J; Weyand CM; Goronzy JJ
JCI Insight; 2022 Jun; 7(12):. PubMed ID: 35730568
[TBL] [Abstract][Full Text] [Related]
7. CD39 deletion in TCR-engineered T cells enhances antitumour immunity.
Tsai AK; Stromnes IM
Gut; 2024 Apr; 73(5):716-717. PubMed ID: 37898545
[No Abstract] [Full Text] [Related]
8. Endothelial Effects of Simultaneous Expression of Human HO-1, E5NT, and ENTPD1 in a Mouse.
Mierzejewska P; Di Marzo N; Zabielska-Kaczorowska MA; Walczak I; Slominska EM; Lavitrano M; Giovannoni R; Kutryb-Zajac B; Smolenski RT
Pharmaceuticals (Basel); 2023 Oct; 16(10):. PubMed ID: 37895880
[TBL] [Abstract][Full Text] [Related]
9. CD39/ENTPD1 expression by CD4+Foxp3+ regulatory T cells promotes hepatic metastatic tumor growth in mice.
Sun X; Wu Y; Gao W; Enjyoji K; Csizmadia E; Müller CE; Murakami T; Robson SC
Gastroenterology; 2010 Sep; 139(3):1030-40. PubMed ID: 20546740
[TBL] [Abstract][Full Text] [Related]
10. ENTPD1/CD39 is a promising therapeutic target in oncology.
Bastid J; Cottalorda-Regairaz A; Alberici G; Bonnefoy N; Eliaou JF; Bensussan A
Oncogene; 2013 Apr; 32(14):1743-51. PubMed ID: 22751118
[TBL] [Abstract][Full Text] [Related]
11. Platelets induce CD39 expression in tumor cells to facilitate tumor metastasis.
Ning Z; Liu K; Zhang H; Dong G; Wang X; Xiong H
Br J Cancer; 2024 May; 130(9):1542-1551. PubMed ID: 38461171
[TBL] [Abstract][Full Text] [Related]
12. Unlocking antitumor immunity with adenosine receptor blockers.
Remley VA; Linden J; Bauer TW; Dimastromatteo J
Cancer Drug Resist; 2023; 6(4):748-767. PubMed ID: 38263981
[TBL] [Abstract][Full Text] [Related]
13. NTPDase1/CD39 Ectonucleotidase Is Necessary for Normal Arterial Diameter Adaptation to Flow.
Favre J; Roy C; Guihot AL; Drouin A; Laprise M; Gillis MA; Robson SC; Thorin E; Sévigny J; Henrion D; Kauffenstein G
Int J Mol Sci; 2023 Oct; 24(20):. PubMed ID: 37894719
[TBL] [Abstract][Full Text] [Related]
14. Targets of Immune Escape Mechanisms in Cancer: Basis for Development and Evolution of Cancer Immune Checkpoint Inhibitors.
Dutta S; Ganguly A; Chatterjee K; Spada S; Mukherjee S
Biology (Basel); 2023 Jan; 12(2):. PubMed ID: 36829496
[TBL] [Abstract][Full Text] [Related]
15. Proteomics of High-Grade Serous Ovarian Cancer Models Identifies Cancer-Associated Fibroblast Markers Associated with Clinical Outcomes.
Govindarajan M; Ignatchenko V; Ailles L; Kislinger T
Biomolecules; 2022 Dec; 13(1):. PubMed ID: 36671461
[TBL] [Abstract][Full Text] [Related]
16. Glycoengineered anti-CD39 promotes anticancer responses by depleting suppressive cells and inhibiting angiogenesis in tumor models.
Zhang H; Feng L; de Andrade Mello P; Mao C; Near R; Csizmadia E; Chan LL; Enjyoji K; Gao W; Zhao H; Robson SC
J Clin Invest; 2022 Jul; 132(13):. PubMed ID: 35775486
[TBL] [Abstract][Full Text] [Related]
17. ATP and Adenosine Metabolism in Cancer: Exploitation for Therapeutic Gain.
Yegutkin GG; Boison D
Pharmacol Rev; 2022 Jul; 74(3):797-822. PubMed ID: 35738682
[TBL] [Abstract][Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
